Study of serum levels and skin expression of S100B protein in psoriasis

Abstract

BackgroundS100B protein was reported to be elevated in psoriatic patients' serum, with no previous evaluation of its skin expression, in contrast to the extensively studied S100 protein.ObjectiveTo evaluate the serum level and skin expression of S100B in psoriasis to assess its possible involvement in its pathogenesis.MethodsSerum level of S100B protein was estimated in 40 psoriatic patients of different clinical varieties and 10 healthy controls. S100B protein expression was assessed immunohistochemically in lesional and non-lesional skin of patients and in normal skin of controls. Relation to disease severity was also evaluated.ResultsSerum level of S100B protein was significantly higher in psoriatic patients (0.15±0.03 µg/l) than in controls (0.03±0.007 µg/l) (P-value <0.001) with no significant correlation with PASI score. On comparing grades of S100B protein skin expression in lesional and non-lesional skin biopsies, a statistically significant difference was found (P=0.046) with higher percentage of strong S100B skin expression (60%) in non-lesional than in lesional (42%) skin. All the control biopsies showed negative expression.Study limitationsRelatively small sample size with a limited range of low PASI scores.ConclusionThis study points to a potential link between psoriasis and S100B protein with higher serum and skin expression in patients than in controls.

Interferon-β Activity Is Affected by S100B Protein

“…This extended PPI network of S100B protein enables regulation of numerous vital processes, such as cell proliferation, differentiation and locomotion, cytoskeleton organization, Ca 2+ homeostasis, protein degradation and phosphorylation, receptors, enzymes and transcription factors [36]. S100B is associated with multiple sclerosis, cancer, SARS-CoV-2, acute neural injury, Alzheimer's and Parkinson's diseases, amyotrophic lateral sclerosis, schizophrenia, epilepsy, bipolar disorder, depression, obesity, diabetes, inflammatory bowel disease, psoriasis, muscular dystrophy, and uveal and retinal disorders [39][40][41][42][43][44]. S100B is clinically used for diagnostics of melanoma, breast cancer, and brain injury [45].…”

Serum level of S100B in vitiligo patients: Is it a marker of disease activity?

“…Also, its level was in proportion to the activity using the PASI score. Therefore, a potential link both S100B level and psoriasis was suggested 22,26 …”

“…Therefore, a potential link both S100B level and psoriasis was suggested. 22,26 Interestingly, Portela et al evaluated the serum level of S100B in patients with SLE, and they discovered that active SLE with brain involvement had higher serum levels of S100B compared to SLE patients without brain involvement. 21 In addition, excessive serum S100B level was thought to be associated with brain ischaemia and is correlated with the extent of brain damage.…”

Multifunctional Role of S100 Protein Family in the Immune System: An Update

“…Small subsets of S100 (for example, S100A7, S100A8, S100A9, and S100A12) have been shown to be upregulated in psoriasis skin lesions, whereas transcriptomics and ELISA-based approaches indicate that S100A12 is strongly correlated with a functional disease condition [ 134 , 135 ] ( Figure 6 ). S100A4 [ 136 ] and S100B [ 137 ] have also been implicated in the pathogenesis of psoriasis. In support of the preceding finding, new research has revealed significantly elevated expression of alarmins, such as IL-33, HMGB1, S100A7, and S100A12, in serum, implying a role for these alarmins in the immunopathology of psoriasis conditions [ 138 ].…”